The National Health Service in England will provide a new cream called ruxolitinib for treating non-segmental vitiligo, targeting the immune cells that cause skin pigmentation loss. Clinical trials showed it increased pigmentation in affected areas, offering a more targeted approach than existing options. The decision follows a reassessment by the National Institute for Health and Care Excellence, making it available for those aged 12 and older when other treatments fail.
Vitiligo affects about 1 percent of the global population, causing symmetrical white patches on the skin due to the immune system attacking melanocytes, the cells responsible for producing melanin. The condition, while not physically painful, can lead to emotional challenges and increased risks of depression and anxiety.
Ruxolitinib, marketed as Opzelura in the United States, is the first treatment robustly tested to act directly on the pathway causing vitiligo. It works by inhibiting two enzymes that prompt immune cells to destroy melanocytes. Two clinical trials led by David Rosmarin at Indiana University, published in 2022, demonstrated that the cream increased pigmentation and reduced the visibility of patches compared to a placebo. These improvements occurred across various skin tones and persisted for at least a year in more than a third of participants after discontinuing use.
Previously, the National Institute for Health and Care Excellence deemed ruxolitinib not cost-effective for NHS use. However, it now recommends the cream for individuals aged 12 and older with non-segmental vitiligo if other topical treatments are unsuitable or ineffective. Emma Rush at Vitiligo Support UK described the approval as a landmark, noting its direct action on the condition's cause.
Existing options like steroid creams broadly suppress the immune system and can thin the skin with prolonged use, while ultraviolet therapy is not widely available. The topical ruxolitinib showed only mild side effects, such as acne and itchiness, with minimal systemic absorption. Viktoria Eleftheriadou at the British Association of Dermatologists highlighted that despite vitiligo not being life-threatening, treatment addresses its psychological impact.
Some individuals embrace their condition without treatment. Vitiligo ambassador Natalie Ambersley for Changing Faces stated, “I’ve learned to accept my skin. We’re [all] unique and we can embrace what we look like.” Rush added, “It’s great that there are people who love the skin they’re in, but that’s not for everyone.” Rosmarin noted, “Usually, people [with vitiligo] are asymptomatic in terms of physical symptoms, but it can cause a lot of emotional hardship.”
